|
gptkbp:instanceOf
|
gptkb:antibiotic
|
|
gptkbp:ATCCode
|
gptkb:J01FA09
|
|
gptkbp:bioavailability
|
50%
|
|
gptkbp:brand
|
gptkb:Biaxin
gptkb:Klaricid
|
|
gptkbp:CASNumber
|
81103-11-9
|
|
gptkbp:category
|
gptkb:antibacterial_drug
|
|
gptkbp:contraindication
|
hypersensitivity to macrolides
concomitant use with certain drugs (e.g., statins, ergot derivatives)
|
|
gptkbp:discoveredBy
|
gptkb:Taisho_Pharmaceutical
|
|
gptkbp:drugClass
|
gptkb:macrolide
|
|
gptkbp:eliminationHalfLife
|
3–7 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:hasMolecularFormula
|
C38H69NO13
|
|
gptkbp:interactsWith
|
gptkb:rifampicin
gptkb:ergot_alkaloids
gptkb:cyclosporine
gptkb:phenytoin
gptkb:theophylline
gptkb:warfarin
gptkb:carbamazepine
gptkb:digoxin
calcium channel blockers
statins
colchicine
HIV protease inhibitors
|
|
gptkbp:introducedIn
|
1991
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits bacterial protein synthesis
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:proteinBinding
|
70–80%
|
|
gptkbp:relatedTo
|
gptkb:azithromycin
gptkb:erythromycin
|
|
gptkbp:riskOfQTProlongation
|
yes
|
|
gptkbp:routeOfAdministration
|
oral
intravenous
|
|
gptkbp:sideEffect
|
nausea
diarrhea
abdominal pain
taste disturbance
|
|
gptkbp:target
|
50S ribosomal subunit
|
|
gptkbp:usedFor
|
skin infections
bacterial infections
respiratory tract infections
Helicobacter pylori eradication
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:Zentiva
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Clarithromycin
|